These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
294 related items for PubMed ID: 10219319
1. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. Grogl M, Schuster BG, Ellis WY, Berman JD. J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319 [Abstract] [Full Text] [Related]
2. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R. Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664 [Abstract] [Full Text] [Related]
3. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. Aguiar MG, Silva DL, Nunan FA, Nunan EA, Fernandes AP, Ferreira LA. J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819 [Abstract] [Full Text] [Related]
4. Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin. Carter KC, Alexander J, Baillie AJ. Ann Trop Med Parasitol; 1989 Jun; 83(3):233-9. PubMed ID: 2604461 [Abstract] [Full Text] [Related]
5. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Soto J, Fuya P, Herrera R, Berman J. Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509 [Abstract] [Full Text] [Related]
7. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Shazad B, Abbaszadeh B, Khamesipour A. Eur J Dermatol; 2005 Jan; 15(2):85-7. PubMed ID: 15757817 [Abstract] [Full Text] [Related]
9. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)]. Schallreuter KU, Lemke KR. Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205 [Abstract] [Full Text] [Related]
10. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Gonçalves GS, Fernandes AP, Souza RC, Cardoso JE, de Oliveira-Silva F, Maciel FC, Rabello A, Ferreira LA. Acta Trop; 2005 Feb; 93(2):161-7. PubMed ID: 15652330 [Abstract] [Full Text] [Related]
11. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. el-On J, Sulitzeanu A, Schnur LF. Ann Trop Med Parasitol; 1991 Jun; 85(3):323-8. PubMed ID: 1746981 [Abstract] [Full Text] [Related]
12. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. N Engl J Med; 2013 Feb 07; 368(6):524-32. PubMed ID: 23388004 [Abstract] [Full Text] [Related]
13. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. El-On J, Bazarsky E, Sneir R. Exp Parasitol; 2007 Jun 07; 116(2):156-62. PubMed ID: 17306255 [Abstract] [Full Text] [Related]
14. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Mussi SV, Fernandes AP, Ferreira LA. Parasitol Res; 2007 May 07; 100(6):1221-6. PubMed ID: 17206508 [Abstract] [Full Text] [Related]
15. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study. Krause G, Kroeger A. Clin Infect Dis; 1999 Aug 07; 29(2):466-7. PubMed ID: 10476776 [No Abstract] [Full Text] [Related]
16. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Soto J, Hernandez N, Mejia H, Grogl M, Berman J. Clin Infect Dis; 1995 Jan 07; 20(1):47-51. PubMed ID: 7727669 [Abstract] [Full Text] [Related]
17. Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice. Fernandes AP, Carvalho FA, Tavares CA, Santiago HC, Castro GA, Tafuri WL, Ferreira LA, Gazzinelli RT. J Infect Dis; 2001 Jun 01; 183(11):1646-52. PubMed ID: 11343214 [Abstract] [Full Text] [Related]
18. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Asilian A, Davami M. Clin Exp Dermatol; 2006 Sep 01; 31(5):634-7. PubMed ID: 16780497 [Abstract] [Full Text] [Related]
19. Treatment of New World cutaneous and mucosal leishmaniases. Berman JD. Clin Dermatol; 1996 Sep 01; 14(5):519-22. PubMed ID: 8889330 [Abstract] [Full Text] [Related]
20. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. Kim DH, Chung HJ, Bleys J, Ghohestani RF. PLoS Negl Trop Dis; 2009 Sep 01; 3(2):e381. PubMed ID: 19221595 [Abstract] [Full Text] [Related] Page: [Next] [New Search]